Calendar

Week of Apr 20, 2026

Apr 24, 2026patent expiry74d agoDaiichi Sankyo Co Ltd — laninamivir (Constraining Patent Expiry (Japan))laninamivir

Therapy area: Infectious Disease, Respiratory. Indication: Asthma, Influenzavirus A Infections, Influenzavirus B Infections

full page →laninamivir →source: globaldata

Apr 24, 2026patent expiry74d agoEisai Co Ltd — lenvatinib mesylate (Constraining Patent Expiry (US))lenvatinib mesylate

Therapy area: Gastrointestinal, Infectious Disease, Oncology. Indication: Acral Lentiginous Melanoma, Adenocarcinoma Of The Gastroesophageal Junction, Adenoid Cystic Carcinoma (ACC), Adrenocortical Carcinoma (Adrenal Cortex Cancer), Anaplastic Thyroid Cancer, Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Breast Cancer, Colorectal Cancer, Cutaneous Squamous Cell Carcinoma (cSCC), Endometrial Cancer, Ependymoma, Epithelial Ovarian Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Ewing S

full page →lenvatinib mesylate →source: globaldata

Apr 24, 2026drug expiry74d agoDaiichi Sankyo Co Ltd — laninamivir (Drug Expiry (Japan))laninamivir

Therapy area: Infectious Disease, Respiratory. Indication: Asthma, Influenzavirus A Infections, Influenzavirus B Infections

full page →laninamivir →source: globaldata

Apr 24, 2026drug expiry74d agoEisai Co Ltd — lenvatinib mesylate (Drug Expiry (US))lenvatinib mesylate

full page →lenvatinib mesylate →source: globaldata

Apr 24, 2026phase 1 initiation74d agoBeijing Friendship Hospital — CMSD-001 (Phase I Trial Initiation)CMSD-001

Therapy area: Dermatology, Immunology. Indication: Atopic Dermatitis (Atopic Eczema), Plaque Psoriasis (Psoriasis Vulgaris), Systemic Lupus Erythematosus

full page →CMSD-001 →source: globaldata

Apr 24, 2026phase 1 results74d agoWroclaw Medical University — viral-specific T-cells (Phase I Trial Results)viral-specific T-cells

Therapy area: Hematological Disorders, Infectious Disease, Oncology. Indication: Aplastic Anemia, Cytomegalovirus (HHV-5) Infections, Hemophagocytic Lymphohistiocytosis, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Refractory Acute Myeloid Leukemia, Viral Infections

full page →viral-specific T-cells →source: globaldata

Apr 24, 2026phase 2 completion74d agoAlentis Therapeutics AG — lixudebart (Phase II Trial Completion)lixudebart

Therapy area: Genito Urinary System, Immunology. Indication: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis), Glomerulonephritis, Kidney Fibrosis

full page →lixudebart →source: globaldata

Apr 24, 2026phase iv trial initiation74d agoAll India Institute of Medical Sciences Jodhpur — melatonin (Phase IV Trial Initiation)melatonin

Therapy area: Central Nervous System, Immunology. Indication: Delirium, Inflammation

full page →melatonin →source: globaldata

Apr 25, 2026phase 1 completion73d agoChangchun Bcht Biotechnology Co Ltd — influenza (trivalent, split virion) vaccine (Phase I Trial Completion)influenza (trivalent, split virion) vaccine

Therapy area: Infectious Disease. Indication: Unspecified Influenza Virus Infections

full page →influenza (trivalent, split virion) vaccine →source: globaldata

Apr 25, 2026phase 1 completion73d agoBristar Immunotech Biotechnology Co Ltd — YTS-109 (Phase I Trial Completion)YTS-109

Therapy area: Hematological Disorders, Immunology. Indication: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), Lupus Nephritis, Thrombocytopenia

full page →YTS-109 →source: globaldata

Apr 25, 2026phase 1 completion73d agoShenzhen Salubris Pharmaceuticals Co Ltd — (alisartan calcium + amlodipine besylate + sacubitril) (Phase I Trial Completion)(alisartan calcium + amlodipine besylate + sacubitril)

Therapy area: Cardiovascular. Indication: Hypertension

full page →(alisartan calcium + amlodipine besylate + sacubitril) →source: globaldata

Apr 25, 2026phase 2 completion73d agoTamilnadu Government Dental College and Hospital — Gengigel (Phase II Trial Completion)Gengigel

Therapy area: Infectious Disease. Indication: Dental Abscess

full page →Gengigel →source: globaldata

Apr 25, 2026phase 2 completion73d agoEmami Ltd — Himani fast relief gel (Phase II Trial Completion)Himani fast relief gel

Therapy area: Central Nervous System, Immunology, Musculoskeletal Disorders. Indication: Inflammation, Myalgia (Muscle Pain), Unspecified Musculoskeletal Disorders

full page →Himani fast relief gel →source: globaldata

Apr 25, 2026phase 2 initiation73d agoGSK plc — dostarlimab (Phase II Trial Initiation)dostarlimab

Therapy area: Infectious Disease. Indication: Hepatitis B

full page →dostarlimab →source: globaldata

Apr 25, 2026phase 2 initiation73d agoKIMS Hospital — bifidobacterium (Phase II Trial Initiation)bifidobacterium

Therapy area: Immunology. Indication: Plaque Psoriasis (Psoriasis Vulgaris), Psoriasis

full page →bifidobacterium →source: globaldata

Apr 25, 2026phase 3 initiation73d agoDr. Reddy's Laboratories Ltd — olokizumab (Phase III Trial Initiation)olokizumab

Therapy area: Immunology. Indication: Rheumatoid Arthritis

full page →olokizumab →source: globaldata

Apr 26, 2026phase 1 2 completion72d agoMahatma Gandhi Ayurved College Hospital and research centre — ayurvedic medicine (Phase I/II Trial Completion)ayurvedic medicine

Therapy area: Cardiovascular. Indication: Thrombophlebitis

full page →ayurvedic medicine →source: globaldata

Apr 26, 2026phase 2 completion72d agoUniversity Health Network — decidual stromal cells (Phase II Trial Completion)decidual stromal cells

Therapy area: Immunology. Indication: Graft Versus Host Disease (GVHD)

full page →decidual stromal cells →source: globaldata

Apr 26, 2026phase 2 completion72d agoBangalore Medical College and Research Institute — bupivacaine (Phase II Trial Completion)bupivacaine

Therapy area: Infectious Disease, Women's Health. Indication: Labor And Delivery, Pregnancy, Puerperal Infection

full page →bupivacaine →source: globaldata

Apr 26, 2026phase 2 initiation72d agoTianFang Pharmaceutical Co — diclofenac sodium DR (Phase II Trial Initiation)DICLOFENAC SODIUM

Therapy area: Central Nervous System, Immunology, Musculoskeletal Disorders, Other Diseases, Women's Health. Indication: Dental Pain (Toothache/Tooth Pain), Dysmenorrhea, Gouty Arthritis (Gout), Injury, Myalgia (Muscle Pain), Osteoarthritis, Pain, Post-Operative Pain, Rheumatic Disorders, Rheumatoid Arthritis, Spondyloarthritis (Spondyloarthropathy), Tenosynovitis

full page →DICLOFENAC SODIUM →source: globaldata

Apr 26, 2026phase 2 results72d agoMinistry of Education University and Research, Italy — artichoke (Phase II Trial Results)artichoke

Therapy area: Cardiovascular, Gastrointestinal. Indication: Endothelial Dysfunction, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD or NAFLD)

full page →artichoke →source: globaldata

Apr 26, 2026phase 3 completion72d agoHubei Provincial Center for Disease Control and Prevention — rabies vaccine (Phase III Trial Completion)rabies vaccine

Therapy area: Infectious Disease. Indication: Rabies

full page →rabies vaccine →source: globaldata

Apr 26, 2026phase 3 completion72d agoTehran University of Medical Sciences — diltiazem (Phase III Trial Completion)diltiazem

Therapy area: Cardiovascular. Indication: Unspecified Cardiovascular Disorders

full page →diltiazem →source: globaldata

Apr 26, 2026phase 3 initiation72d agoStanford University — zanubrutinib (Phase III Trial Initiation)zanubrutinib

Therapy area: Immunology. Indication: Immunoglobulin G4-Related Disease (IgG4-RD)

full page →zanubrutinib →source: globaldata

Week of Apr 27, 2026

Apr 27, 2026phase 1 initiation71d agoNational Institute of Neurological Disorders and Stroke — pembrolizumab (Phase I Trial Initiation)pembrolizumab

Therapy area: Infectious Disease. Indication: Coronavirus Disease 2019 (COVID-19), Post-Acute Sequelae of COVID 2019 (PASC or Long COVID)

full page →pembrolizumab →source: globaldata

Apr 27, 2026constraining patent expiry europe

← prev

page 1 of 3

Week of Apr 20, 2026

Week of Apr 27, 2026